During the past decade, Manhattan Behavioral Medicine conducted 45 clinical trials. In the 10-year time frame, 45 clinical trials started and 25 clinical trials were completed, i.e. on average, 55.6% percent of trials that started reached the finish line to date. In the past 5 years, 19 clinical trials started and 24 clinical trials were completed. i.e. 126.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Manhattan Behavioral Medicine" #1 sponsor was "Otsuka Pharmaceutical Development & Commercialization, Inc." with 7 trials, followed by "Forest Laboratories" with 4 trials sponsored, "Naurex, Inc, an affiliate of Allergan plc" with 4 trials sponsored, "Janssen Research & Development, LLC" with 3 trials sponsored and "ACADIA Pharmaceuticals Inc." with 3 trials sponsored. Other sponsors include 21 different institutions and companies that sponsored additional 28 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Manhattan Behavioral Medicine" #1 collaborator was "APCER Life Sciences" with 1 trials as a collaborator, "Alzheimer's Association" with 1 trials as a collaborator, "Amsterdam UMC, location VUmc" with 1 trials as a collaborator, "Clinilabs, Inc." with 1 trials as a collaborator and "KCAS Bio" with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "Manhattan Behavioral Medicine" are "Depressive Disorder, Major" (8 trials), "Major Depressive Disorder" (8 trials), "Schizophrenia" (5 trials), "Alzheimer's Disease" (4 trials) and "Alzheimer Disease" (3 trials). Many other conditions were trialed in "Manhattan Behavioral Medicine" in a lesser frequency.

Most popular intervention types in "Manhattan Behavioral Medicine" are "Drug" (45 trials), "Other" (6 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (28 trials), "Rapastinel" (4 trials), "AVP-786" (3 trials), "Fluoxetine" (3 trials) and "Aticaprant" (2 trials). Other intervention names were less common.

The vast majority of trials in "Manhattan Behavioral Medicine" are 46 trials for "All" genders.

Currently, there are NaN active trials in "Manhattan Behavioral Medicine". undefined are not yet recruiting, 8 are recruiting, undefined are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 29 completed trials in Manhattan Behavioral Medicine, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Manhattan Behavioral Medicine, 1 "Phase 1" clinical trials were conducted, 15 "Phase 2" clinical trials and 29 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".